Details

Autor(en) / Beteiligte

• Pilishvili, Tamara
• Fleming-Dutra, Katherine E
• Farrar, Jennifer L
• Gierke, Ryan
• Mohr, Nicholas M
• Talan, David A
• Krishnadasan, Anusha
• Harland, Karisa K
• Smithline, Howard A
• Hou, Peter C
• Lee, Lilly C
• Lim, Stephen C
• Moran, Gregory J
• Krebs, Elizabeth
• Steele, Mark
• Beiser, David G
• Faine, Brett
• Haran, John P
• Nandi, Utsav
• Schrading, Walter A
• Chinnock, Brian
• Henning, Daniel J
• LoVecchio, Frank
• Nadle, Joelle
• Barter, Devra
• Brackney, Monica
• Britton, Amber
• Marceaux-Galli, Kaytlynn
• Lim, Sarah
• Phipps, Erin C
• Dumyati, Ghinwa
• Pierce, Rebecca
• Markus, Tiffanie M
• Anderson, Deverick J
• Debes, Amanda K
• Lin, Michael
• Mayer, Jeanmarie
• Babcock, Hilary M
• Safdar, Nasia
• Fischer, Marc
• Singleton, Rosalyn
• Chea, Nora
• Magill, Shelley S
• Verani, Jennifer
• Schrag, Stephanie

Titel

Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021

Ist Teil von

• MMWR. Morbidity and mortality weekly report, 2021-05, Vol.70 (20), p.753-758

Ort / Verlag

United States: U.S. Government Printing Office

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Throughout the COVID-19 pandemic, health care personnel (HCP) have been at high risk for exposure to SARS-CoV-2, the virus that causes COVID-19, through patient interactions and community exposure (1). The Advisory Committee on Immunization Practices recommended prioritization of HCP for COVID-19 vaccination to maintain provision of critical services and reduce spread of infection in health care settings (2). Early distribution of two mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) to HCP allowed assessment of the effectiveness of these vaccines in a real-world setting. A test-negative case-control study is underway to evaluate mRNA COVID-19 vaccine effectiveness (VE) against symptomatic illness among HCP at 33 U.S. sites across 25 U.S. states. Interim analyses indicated that the VE of a single dose (measured 14 days after the first dose through 6 days after the second dose) was 82% (95% confidence interval [CI] = 74%-87%), adjusted for age, race/ethnicity, and underlying medical conditions. The adjusted VE of 2 doses (measured ≥7 days after the second dose) was 94% (95% CI = 87%-97%). VE of partial (1-dose) and complete (2-dose) vaccination in this population is comparable to that reported from clinical trials and recent observational studies, supporting the effectiveness of mRNA COVID-19 vaccines against symptomatic disease in adults, with strong 2-dose protection.